BioSpace News Archive

BioMidwest

Accuray to Participate in the 14th Annual Jefferies London Healthcare Conference

Accuray Incorporated announced its participation in the 14th Annual Jefferies London Healthcare Conference.

October 31, 2023
·
1 min read
BioMidwest

Surmodics Announces Launch of Preside™ Medical Device Coating Technology, Providing Industry-Leading Lubricity and Durability to a Broader Range of Complex Device Applications

Surmodics, Inc. (NASDAQ: SRDX), the global leader in medical device coating technologies, announced the commercial launch of its most advanced hydrophilic medical device coating technology, Preside™ hydrophilic coatings.

October 31, 2023
·
3 min read
Business

ImmPACT Bio Appoints Han Lee, Ph.D., MBA, as President and Chief Financial Officer

ImmPACT Bio USA, Inc., a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor T-cell therapies for treating cancer and autoimmune diseases, announced the appointment of Han Lee, Ph.D., MBA, as president and chief financial officer.

October 31, 2023
·
3 min read
BioMidwest

MBX Biosciences to Participate in Stifel 2023 Healthcare Conference

MBX Biosciences, Inc. announced that Kent Hawryluk, President and Chief Executive Officer, will present at the Stifel 2023 Healthcare Conference on Tuesday, November 14th, 2023, at 2:25 p.m. Eastern Time and will host 1-on-1 investor meetings.

October 31, 2023
·
1 min read
Business

CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023

CytomX Therapeutics, Inc. today announced that it will report third quarter financial results on Tuesday, November 7, 2023, after the close of U.S. markets.

October 31, 2023
·
2 min read
Business

Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8:00 a.m. ET

Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”) today announced that it will report results for the third quarter ended September 30, 2023 and provide an update on recent developments in its business after market close on Monday, November 6, 2023.

October 31, 2023
·
3 min read
Deals

PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101

PaxMedica, Inc. (Nasdaq: PXMD), a pioneering biopharmaceutical company specializing in cutting-edge treatments for neurological disorders, announced today the successful acquisition of certain suramin research assets from Rediscovery Life Sciences (RLS).

October 31, 2023
·
4 min read
Drug Development

Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056

Mersana Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the company’s Phase 1 clinical trial of XMT-2056.

October 31, 2023
·
4 min read
BioForest

Icosavax to Participate in the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference

Icosavax, Inc. today announced that the company will participate in and host one-on-one meetings at the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference, taking place from November 6-7, 2023 in New York City.

October 31, 2023
·
1 min read
INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority

INmune Bio, Inc. announced an update regarding the company’s patent covering its proprietary cell line, “INB16”.

October 31, 2023
·
9 min read